# Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

> **NCT04497792** · PHASE4 · COMPLETED · sponsor: **Research Institute for Complex Problems of Cardiovascular Diseases, Russia** · enrollment: 40 (actual)

## Conditions studied

- Coronary Artery Disease
- Diabetes Mellitus
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Empagliflozin 10Mg Tab
- **DRUG:** hypoglycemic therapy

## Key facts

- **NCT ID:** NCT04497792
- **Lead sponsor:** Research Institute for Complex Problems of Cardiovascular Diseases, Russia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-11
- **Final completion:** 2019-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04497792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04497792, "Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04497792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*